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ABSTRACT
Background: Heart failure (HF) is a major source of morbidity and
mortality, particularly among the elderly. Magnesium, phosphorus,
and calcium are micronutrients traditionally viewed in relation to
bone health or chronic kidney disease. However, they also may be
associated with risk of cardiovascular disease through a broad range
of physiologic roles.
Objective: With the use of data from the Atherosclerosis Risk in
Communities (ARIC) cohort, we tested the hypotheses that the in-
cidence of HF is greater among individuals with low serum mag-
nesium and those with high serum phosphorus and calcium.
Design: A total of 14,709 African Americans (27%) and whites
from the ARIC cohort [aged 45–64 y at baseline (1987–1989)] were
observed through 2009. Proportional hazards regression was used to
explore associations between biomarkers and incident HF. Serum
calcium was corrected for serum albumin. Models were adjusted for
demographics, behaviors, and physiologic characteristics.
Results: A total of 2250 incident HF events accrued over a median
follow-up of 20.6 y. Participants in the lowest (#1.4 mEq/L) com-
pared with the highest ($1.8 mEq/L) category of magnesium were
at greater HF risk (HR: 1.71; 95% CI: 1.46, 1.99). For phosphorus,
there appeared to be a threshold whereby only those in the highest
quintile were at greater HF risk [HR(Q5 vs Q1): 1.34; 95% CI: 1.16,
1.54]. Higher concentrations of calcium were also associated with
greater risk of HF [HR(Q5 vs Q1): 1.24; 95% CI: 1.07, 1.43]. Results
were not modified by race, sex, or kidney function and were similar
when incident coronary heart disease was included as a time-varying
covariate.
Conclusions: Low serum magnesium and high serum phosphorus
and calcium were independently associated with greater risk of
incident HF in this population-based cohort. Whether these bio-
markers will be useful candidates for HF risk prediction or targets
for prevention remains to be seen. Am J Clin Nutr 2014;
100:756–64.
INTRODUCTION
Heart failure (HF)4 is a common cause of morbidity and
mortality in the developed world. At 40 y of age, the lifetime
risk for developing HF is 20% for both men and women (1).
Although some risk factors for HF are firmly established [eg,
increasing age, hypertension, diabetes, and antecedent myocar-
dial infarction (MI)] (2), given the high societal burden of HF,
there is interest in identifying new characteristics that may be
associated with HF development.
Magnesium, phosphorus, and calcium are micronutrients
traditionally viewed in relation to bone health or chronic kidney
disease. However, they also may be associated with the risk of
cardiovascular disease (CVD). Magnesium is believed to be
linked to CVD risk through a broad range of physiologic roles;
low serum concentrations have been associated with impaired
glucose homeostasis and insulin action, elevated blood pressure,
chronic inflammation, impaired vasomotor tone and peripheral
blood flow, and electrocardiogram abnormalities (3). Elevated
serum phosphorus is hypothesized to influence CVD risk through
vascular calcification (4), myocardial fibrosis (5), and development
of left ventricular hypertrophy (6). Higher serum calcium con-
centrations may promote CVD and atherogenesis through vas-
cular calcification and increased coagulability (7, 8).
Previous studies have explored the relation of magnesium,
phosphorus, and calcium to risk of CVD risk factors (4, 6, 9–13)
and other CVD phenotypes (14–23), but relatively little is
known about the association of these micronutrients to the risk
of HF (13, 24). Using data from the Atherosclerosis Risk
in Communities (ARIC) cohort, we tested the hypotheses that
the incidence of HF is greater among individuals with low
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concentrations of serum magnesium and high concentrations of
serum phosphorus and calcium.
MATERIALS AND METHODS
Study population
The ARIC Study (http://www2.cscc.unc.edu/aric/) is a multi-
center population-based prospective cohort study that includes
15,792 predominantly white and black men and womenwhowere
aged 45–64 y in 1987–1989 (visit 1) and were recruited from
4 US communities: Forsyth County, North Carolina; Jackson,
Mississippi; suburbs of Minneapolis, Minnesota; and Washington
County, Maryland (25). Four cohort reexaminations have taken
place: 1990–1992, 1993–1995, 1996–1998, and 2011–2013. Local
institutional review boards approved the ARIC protocol, and all
participants gave informed consent.
For this analysis, we excluded participants who had prevalent
HF at baseline (n = 752) or were missing information needed to
ascertain HF prevalence (n = 287), as well as those who were
neither African American nor white, and African Americans
from the Minnesota and Maryland centers due to low numbers
(n = 44). Our final analytic sample included 14,709 participants.
Exposure and covariate measurement
At baseline, ARIC participants underwent interviews, fasting
venipuncture, and measurement of blood pressure and anthro-
pometrics. Trained interviewers ascertained basic demographic
data, medical history, and information about personal habits, such
as diet, smoking status, physical activity, and medication use.
Participants were asked to bring all medications, vitamins, and
supplements taken in the 2 wk before the examination; all
medication names were transcribed and coded. Height and weight
were measured, with BMI calculated as weight (in kg) divided by
the square of height (in m). Sitting blood pressure was measured
in triplicate with a random-zero sphygmomanometer; the average
of the latter 2 measurements were used in this analysis. Diabetes
was defined by fasting blood glucose $126 mg/dL, nonfasting
glucose $200 mg/dL, a self-report of physician diagnosis, or
current medication use for diabetes.
Fasting (12-h) blood samples were drawn, and plasma and
serum were frozen at 2708C until analyzed (26). Serum mag-
nesium was measured by the Gindler and Heth procedure by
using the metallochromic dye calmagite [1-(1-hydroxy-4-
methyl-2-phenylazo)-2-napthol-4sulfonic acid]. Using split
samples sent 1 wk apart, the within-participant laboratory CV
was 3.6%. Serum phosphorus was quantified by using methods
based on ammonium molybdate (CV: 7.6%), serum calcium
with an approach based on o-cresolphthalein complexone (CV:
1.1%), serum albumin with a bromocresol green colorimetric
assay (CV: 2.8%), and serum creatinine by using a modified
kinetic Jaffe–picric acid (CV: 3.7%). As is typically done in
clinical settings, serum calcium was adjusted for serum albumin
by using the following equation: corrected calcium = measured
total calcium (mg/dL) + 0.8 [4.0 2 serum albumin (g/dL)].
Throughout the article, all results reported for calcium are based
on the serum albumin–corrected variable. Measurement of se-
rum magnesium, phosphorus, and calcium was repeated at visit
2 by using similar methods. Estimated glomerular filtration
rate was calculated by using serum creatinine (27) then cate-
gorized according to established clinical cutoffs: $90, 60–89,
and 15–59 mL $ min–1 $ 1.73 m–2.
HF and coronary heart disease ascertainment
Prevalent HF at baseline was defined as the following: 1) an
affirmative response to “Were any of the medications you took
during the last 2 weeks for heart failure?” or 2) stage 3 or “manifest
heart failure” by Gothenburg criteria (28, 29). Prevalent coronary
heart disease (CHD) was defined by self-reported previous phy-
sician diagnosis of MI or coronary revascularization, or prevalent
MI by 12-lead electrocardiogram.
Incident cardiovascular events through 31 December 31 2009
were identified through annual telephone calls to ARIC cohort
participants to identify all hospitalizations, review of local hospital
discharge indexes, and retrieval of death certificates. HF incidence
was defined as the first occurrence of either a hospitalization that
included an International Classification of Diseases, 9th Revision
(ICD-9) discharge code of 428 (428.0–428.9) among the primary
or secondary diagnoses or else a death certificate with an ICD-9
code of 428 or an International Classification of Diseases, 10th
Revision code of I50 among any of the listed diagnoses or un-
derlying causes of death (29). ARIC has shown the validity of
ICD-9 code 428 to be moderately high compared with medical
record review, with a sensitivity of 93% for identifying acute
decompensated heart failure (30). Incident CHD was defined by
a definite or probable MI, coronary angioplasty, coronary artery
bypass surgery, or CHD death, according to previously described
procedures (31).
Data analysis
Baseline characteristics of participants are described by using
means and proportions stratified by levels of the exposures. Cox
proportional hazards regression was used to explore associations
between serum magnesium, phosphorus, calcium, and risk of
incident HF. Restricted cubic splines were used to visually depict
the associations. In the spline models, biomarker values were
truncated at the 1st and 99th percentiles to minimize the influence
of extreme values at either tail of the distributions. Serum
magnesium values were reported to only one decimal place;
therefore, we were not able to categorize serum magnesium as
equal quintiles. As such, a priori, we categorized serum mag-
nesium in a manner that most closely approximated quintiles. The
highest category was used as the reference. Serum phosphorus
and calcium were modeled as quintiles, with the lowest group
being the reference. P values are reported for the linear trends
across the quintiles.
Our first model adjusted for age, sex, race, and ARIC field
center. Model 2 also adjusted for baseline behavioral charac-
teristics (education, physical activity, and smoking status) and
BMI. Model 3 further adjusted for prevalent diabetes and CHD,
as well as baseline estimated glomerular filtration rate categories,
systolic blood pressure, any hypertension medication use in the
past 2 wk, LDL cholesterol, HDL cholesterol, triglycerides, and
antihyperlipidemic medication use in the past 2 wk. In model 4,
incident CHD was included as a time-dependent covariate.
Interaction terms were used to evaluate whether race, sex,
hypertension, diabetes, kidney function, or prevalent MI modified
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the associations of serum magnesium, phosphorus, and calcium to
the risk of incident HF. The proportional hazards assumption was
evaluated quantitatively by testing the interaction between the
biomarkers and ln(time) and qualitatively by inspection of ln(2ln)
survival curves for biomarker categories. For serum magnesium,
sensitivity analyses were conducted adjusting for alcohol intake
(g/d) as a covariate, because heavy alcohol intake is associated
with low magnesium concentrations. For both magnesium and
calcium, sensitivity analyses excluded participants taking diuretics
(n = 2114), because diuretics have been shown to lower serum
magnesium and calcium concentrations.
RESULTS
Our final analytic sample included 14,709 ARIC participants
who at baseline had a mean age of 54.1 y and were 54.5% female
and 26.5% African American. The mean 6 SD concentration was
1.636 0.16 mEq/L for serum magnesium, 3.436 0.49 mg/dL for
serum phosphorus, and 9.88 6 0.42 mg/dL for serum calcium.
These biomarkers were weakly correlated (although all P ,
0.0001 given ARIC’s large sample size): r = 0.05 for magnesium
and phosphorus, r = 20.06 for magnesium and calcium, and r =
0.16 for phosphorus and calcium.
Baseline characteristics of participants stratified by categories
of serum magnesium, phosphorus, and calcium are presented in
Table 1 and Supplemental Tables 1 and 2 (under “Supplemental
data” in the online issue), respectively. In brief, participants with
higher concentrations of serum magnesium tended to be male,
tended to be white, and overall had a more favorable cardio-
vascular risk factor profile. Conversely, participants with higher
concentrations of serum phosphorus and serum calcium tended
to be female, tended to be African American, and overall had
a worse cardiovascular risk profile.
During a median of 20.6 y of follow-up (maximum: 23.1 y),
a total of 2250 incident HF events accrued. Serum magnesium
showed a linear inverse association with the risk of incident HF
TABLE 1
Participant characteristics by serum magnesium category: the ARIC Study, 1987–1989 (N = 14,709)1
Characteristic
Category
P-trend1 (n = 1719) 2 (n = 2375) 3 (n = 3770) 4 (n = 3660) 5 (n = 3185)
Magnesium (mEq/L)2 1.4 (0.5–1.4) 1.5 (1.5–1.5) 1.6 (1.6–1.6) 1.7 (1.7–1.7) 1.8 (1.8–3.1)
Demographic charateristics
Age (y) 54.1 6 5.9 53.8 6 5.8 53.9 6 5.8 54.1 6 5.7 54.3 6 5.6 0.01
Female 1012 (58.9) 1385 (58.3) 2038 (54.1) 1942 (53.0) 1664 (52.2) ,0.0001
African American 904 (52.6) 782 (32.9) 959 (25.4) 697 (19.0) 560 (17.6) ,0.0001
Education ,0.0001
,High school 585 (34.1) 610 (25.7) 815 (21.7) 768 (21.0) 624 (19.6)
High school 615 (35.9) 992 (41.8) 1564 (41.6) 1511 (41.3) 1320 (41.5)
.High school 514 (30.0) 770 (32.5) 1385 (36.8) 1377 (37.7) 1236 (38.9)
Behavioral characteristics
Sport index 2.31 6 0.76 2.36 6 0.77 2.46 6 0.81 2.49 6 0.80 2.49 6 0.80 ,0.0001
Smoking status 0.06
Current 503 (29.3) 608 (25.6) 989 (26.3) 942 (25.7) 772 (24.3)
Former 514 (30.0) 748 (31.6) 1195 (31.7) 1188 (32.5) 1076 (33.8)
Never 699 (40.7) 1015 (42.8) 1583 (42.0) 1529 (41.8) 1335 (41.9)
Alcohol (drinks/wk) 7.6 6 13.0 5.7 6 9.3 5.5 6 8.9 5.6 6 8.4 5.6 6 8.5 0.001
Physiologic characteristics
BMI (kg/m2) 29.2 6 6.2 28.3 6 5.7 27.4 6 5.2 27.1 6 4.8 26.9 6 4.7 ,0.0001
Prevalent diabetes 476 (29.4) 345 (14.6) 383 (10.2) 250 (6.8) 170 (5.3) ,0.0001
Prevalent hypertension 900 (52.5) 936 (39.5) 1169 (31.0) 977 (26.8) 839 (26.4) ,0.0001
Systolic BP (mm Hg) 127 6 21 123 6 19 121 6 19 119 6 18 119 6 18 ,0.0001
Hypertension medication 700 (40.8) 665 (28.1) 811 (21.5) 657 (18.0) 548 (17.2) ,0.0001
Diuretic use 428 (24.9) 389 (16.4) 514 (13.6) 403 (11.0) 347 (10.9) ,0.0001
Lipid-lowering medication 42 (2.5) 69 (2.9) 101 (2.7) 94 (2.6) 90 (2.8) 0.78
HDL cholesterol (mg/dL) 51.1 6 18.7 51.4 6 17.0 51.9 6 17.3 52.1 6 16.8 51.9 6 16.3 0.06
LDL cholesterol (mg/dL) 133 6 42 135 6 39 137 6 40 139 6 38 141 6 39 ,0.0001
Triglycerides (mg/dL) 158 6 130 135 6 91 129 6 84 123 6 76 122 6 76 ,0.0001
eGFR (mL $ min–1 $ 1.73 m–2) 100.1 6 18.2 97.9 6 15.3 96.3 6 14.5 94.8 6 13.6 93.3 6 14.4 ,0.0001
eGFR category ,0.0001
.90 mL $ min–1 $ 1.73 m–2 1196 (74.9) 1752 (73.8) 2639 (70.0) 2493 (68.1) 2066 (65.1)
60–90 mL $ min–1 $ 1.73 m–2 355 (22.2) 597 (24.7) 1084 (28.8) 1132 (30.9) 1042 (32.8)
,60 mL $ min–1 $ 1.73 m–2 46 (2.9) 35 (1.5) 45 (1.2) 34 (0.9) 66 (2.1)
Calcium3 (mg/dL) 9.97 6 0.46 9.89 6 0.42 9.87 6 0.40 9.86 6 0.40 9.87 6 0.41 ,0.0001
Phosphorus (mg/dL) 3.43 6 0.52 3.39 6 0.48 3.42 6 0.49 3.42 6 0.48 3.47 6 0.51 ,0.0001
Prevalent CHD 92 (5.4) 99 (4.2) 144 (3.8) 138 (3.8) 127 (4.0) 0.04
1Values are means 6 SDs for continuous variables and n (%) for categorical variables unless indicated otherwise. ARIC, Atherosclerosis Risk in
Communities; BP, blood pressure; CHD, coronary heart disease; eGFR, estimated glomerular filtration rate.
2Values are medians; ranges in parentheses.
3Corrected for serum albumin concentration.
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(Table 2, Figure 1A). Relative to those in the highest category
of serum magnesium, those in the lowest category were at 2.58
(95% CI: 2.23, 2.97) times greater risk of incident HF after
demographic adjustments. This association was modestly at-
tenuated but remained statistically significant, with adjustment
for behaviors (HR: 2.15; 95% CI: 1.86, 2.48) and further ad-
justment for CVD risk factors (HR: 1.71; 95% CI: 1.46, 1.99)
and incident CHD as a time-varying covariate (HR: 1.66; 95%
CI: 1.42, 1.95). The proportional hazards assumption was sta-
tistically significantly violated for model 1 [P value for mag-
nesium categories*ln(time) = 0.01]. Overall, associations were
stronger earlier in follow-up as opposed to later in follow-up [eg,
for model 1, the HR (95% CI) for extreme categories in the first
10 y was 3.06 (2.40, 3.89), whereas for follow-up after 10 y, it
was 2.31 (1.93, 2.76)]. Associations between magnesium cate-
gories and incident HF stratified by follow-up time are presented
in Supplemental Table 3 (under “Supplemental data” in the
online issue) and Figure 2. In sensitivity analyses, results were
similar when we added alcohol intake to model 2 and when we
excluded 2114 participants who reported using diuretics at
baseline (data not shown).
Serum phosphorus was positively associated with the risk of
incident HF, although the association was nonlinear, with most of
the excess risk observed at higher concentrations of phosphorus
(Table 2, Figure 1B). Individuals in the highest quintile of
phosphorus were 1.42 (95% CI: 1.24, 1.63) times more likely to
develop incident HF relative to their counterparts in the lowest
quintile. The association was attenuated only slightly with the
addition of behaviors (model 2: HR: 1.43; 95% CI: 1.25, 1.64),
CVD risk factors (model 3: HR: 1.34; 95% CI: 1.16, 1.54), and
time-dependent CHD as covariates (model 4: HR: 1.36; 95% CI:
1.18, 1.56). When comparing the top decile of serum phosphorus
with the lowest quintile, the HR for incident HF was 1.52 (95%
CI: 1.30, 1.78) for model 1 and 1.37 (95% CI: 1.16, 1.62) for
model 3. Although the proportional hazards assumptions were
not statistically violated for serum phosphorus models, associ-
ations between phosphorus and incident HF were slightly
stronger during the first 10 y of follow-up as opposed to later in
follow-up (Supplemental Table 3 under “Supplemental data” in
the online issue and Figure 2).
Serum calcium was positively associated with the risk of
incident HF (Table 2, Figure 1C). The HR for those in the highest
compared with the lowest quintile of serum calcium was 1.48
(95% CI: 1.29, 1.70) after adjustment for demographic charac-
teristics. Additional adjustment for behaviors, CVD risk factors,
and CHD incidence had little impact on the estimates (model 4:
HR: 1.41; 95% CI: 1.22, 1.62). Across all models, the pro-
portional hazards assumption was violated: P values for calcium
quintiles (modeled linearly)*ln(time) were 0.0009 for model 1, 0.001
for model 2, 0.01 for model 3, and 0.02 for model 4. As shown in
TABLE 2
Serum magnesium, phosphorus, and calcium and risk of incident heart failure: the ARIC Study, 1987–2009 (N = 14,709)1
Category
Quintile
P-trend1 2 3 4 5
Magnesium (mEq/L)
Median (range) 1.4 (0.5–1.4) 1.5 (1.5–1.5) 1.6 (1.6–1.6) 1.7 (1.7–1.7) 1.8 (1.8–3.1)
No. of events/total 448/1753 421/2423 538/3839 481/3736 362/3242
Incidence rate2 15.89 9.90 7.79 7.04 6.00
Model 1 2.58 (2.23, 2.97)3 1.68 (1.46, 1.94) 1.32 (1.15, 1.50) 1.18 (1.03, 1.35) 1.00 ,0.0001
Model 2 2.15 (1.86, 2.48) 1.52 (1.32, 1.76) 1.25 (1.09, 1.43) 1.14 (1.00, 1.31) 1.00 ,0.0001
Model 3 1.71 (1.46, 1.99) 1.41 (1.21, 1.63) 1.24 (1.08, 1.42) 1.17 (1.02, 1.35) 1.00 ,0.0001
Model 4 1.66 (1.42, 1.95) 1.37 (1.18, 1.59) 1.22 (1.06, 1.40) 1.16 (1.01, 1.34) 1.00 ,0.0001
Phosphorus (mg/dL)
Median (range) 2.8 (1.0–3.0) 3.2 (3.1–3.2) 3.4 (3.3–3.5) 3.7 (3.6–3.8) 4.1 (3.9–9.1)
No. of events/total 489/3253 314/2114 530/3728 422/3059 467/2703
Incidence rate2 8.47 8.22 7.86 7.61 9.78
Model 1 1.00 1.04 (0.90, 1.19) 1.01 (0.89, 1.15) 1.03 (0.90, 1.17) 1.42 (1.24, 1.63) ,0.0001
Model 2 1.00 1.08 (0.93, 1.24) 1.05 (0.92, 1.19) 1.01 (0.88, 1.16) 1.43 (1.25, 1.64) ,0.0001
Model 3 1.00 1.08 (0.93, 1.24) 1.04 (0.91, 1.18) 1.02 (0.89, 1.17) 1.34 (1.16, 1.54) ,0.0001
Model 4 1.00 1.16 (1.00, 1.34) 1.09 (0.96, 1.24) 1.10 (0.96, 1.26) 1.36 (1.18, 1.56) 0.0005
Calcium4 (mg/dL)
Median (range) 9.4 (7.3–9.5) 9.7 (9.5–9.8) 9.9 (9.8–10.0) 10.1 (10.0–10.2) 10.4 (10.2–13.6)
No. of events/total 376/2869 415/3090 426/2964 468/2970 538/2964
Incidence rate2 7.06 7.33 7.95 8.92 10.61
Model 1 1.00 1.07 (0.93, 1.23) 1.12 (0.98, 1.29) 1.28 (1.11, 1.46) 1.48 (1.29, 1.70) ,0.0001
Model 2 1.00 1.06 (0.92, 1.22) 1.09 (0.95, 1.25) 1.22 (1.06, 1.40) 1.36 (1.19, 1.56) 0.002
Model 3 1.00 1.09 (0.94, 1.25) 1.12 (0.97, 1.29) 1.13 (0.98, 1.31) 1.24 (1.07, 1.43) 0.004
Model 4 1.00 1.15 (1.00, 1.33) 1.21 (1.05, 1.40) 1.21 (1.05, 1.40) 1.41 (1.22, 1.62) ,0.0001
1Model 1 was adjusted for age, sex, race, and center. Model 2 was adjusted as for model 1 plus for education, physical activity, smoking status, and BMI.
Model 3 was adjusted as for model 2 plus for prevalent diabetes, systolic blood pressure, hypertension medication use, lipid-lowering medication use,
prevalent CHD, estimated glomerular filtration rate, LDL cholesterol, HDL cholesterol, and triglycerides. Model 4 was adjusted as for model 3 plus for
incident CHD as a time-varying covariate. ARIC, Atherosclerosis Risk in Communities; CHD, coronary heart disease.
2Unadjusted incidence rate per 1000 person-years.
3HR; 95% CI in parentheses (all such values).
4Corrected for serum albumin concentration.
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Supplemental Table 3 (under “Supplemental data” in the online is-
sue) and Figure 2, magnitudes of associations were greater in the
first 10 y of follow-up relative to later in follow-up. Restricting
follow-up to an even shorter period (5 y) resulted in estimates of
slightly greater magnitude, although the CIs were wide because only
293 events occurred during the first 5 y of follow-up [HR(Q5 vs Q1)
(95% CI): 2.71 (1.80, 4.08) for model 1, 2.52 (1.66, 3.81) for model
2, 2.09 (1.33, 3.27) model 3, and 2.45 (1.56, 3.86) for model 4].
In additional analyses, we included all 3 biomarkers simul-
taneously in model 3. The estimates were virtually identical to
FIGURE 1. Association of serum magnesium (A), phosphorus (B), and calcium (C) (corrected for serum albumin concentration) with risk of incident heart
failure: the Atherosclerosis Risk in Communities Study, 1987–2009 (N = 14,709). Biomarkers modeled as restricted cubic splines with knots at the 5th, 27.5th,
50th, 72.5th, and 95th percentiles, with adjustment for age, race, sex, and study center.
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those when the biomarkers were individually included in model
3. HRs (95% CIs) for extreme categories were as follows: 1.72
(1.47, 2.01) for magnesium, 1.35 (1.17, 1.56) for phosphorus, and
1.20 (1.04, 1.38) for calcium. Results were also similar in sen-
sitivity analyses when visit 1 and visit 2 biomarker values were
averaged (data not shown). For all 3 biomarkers, there was
no evidence of effect modification of their associations to in-
cident HF by race, sex, hypertension, diabetes, kidney function,
or prevalent MI. Furthermore, there was no evidence of in-
teractions between the 3 biomarkers on the risk of incident HF.
DISCUSSION
In this large, biracial, population-based cohort study, lower
concentrations of serummagnesium and higher concentrations of
serum phosphorus and calcium were independently associated
with the risk of incident HF. These associations were only
modestly attenuated with adjustment for additional CVD risk
factors, and there was no evidence of interactions by sex, race,
kidney function, or prevalent CHD. For all 3 biomarkers, asso-
ciations were somewhat stronger early in the follow-up period
relative to later in follow-up. This is not surprising because these
biomarkers were measured at baseline, which was often many
years before HF events accrued.
CHD is believed to underlie more than half of the incident HF
cases in the general population younger than 75 y (32). Therefore,
we adjusted for CHD as a time-varying covariate to evaluate
whether our findings were simply the result of these biomarkers
being associated with a greater risk of CHD and CHD associated
with a greater risk of HF. The fact that our results were only
FIGURE 2. HRs and their 95% CIs for extreme categories of serum magnesium, phosphorus, and calcium and risk of incident heart failure, stratified by
follow-up time: the Atherosclerosis Risk in Communities Study, 1987–2009 (N = 14,709). A: Demographics adjusted for age, sex, race, and center (model 1).
B: Adjusted for demographics, behaviors, and cardiovascular disease risk factors, including age, sex, race, center, education, physical activity, smoking status,
BMI, prevalent diabetes, systolic blood pressure, hypertension medication use, lipid-lowering medication use, prevalent coronary heart disease, estimated
glomerular filtration rate, LDL cholesterol, HDL cholesterol, and triglycerides (model 3 in other analyses). HF, heart failure.
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modestly attenuated after more carefully accounting for CHD by
using incident CHD as a time-varying covariate suggests that
these biomarkers may be associated with the risk of HF at least
partly independently of CHD.
Magnesium and HF
Observational studies have linked low serum magnesium to
more adverse CVD risk factor profiles (9–11) and greater risk of
CVD events (14–19). In the present analysis, participants in the
lowest quintile of magnesium were at 2.5 times greater risk of
incident HF after adjustment for demographic factors. With
additional adjustment for behaviors and CVD risk factors (some
of which may be on the causal pathway between magnesium and
HF), individuals in the lowest quintile of magnesium were at
66% greater risk of developing incident HF than those in the
highest quintile. Serum magnesium concentrations were lower
among African Americans than among whites (mean: 1.58
compared with 1.65 mEq/L), and thus low serum magnesium
may be an additional factor underlying the higher risk of HF
among African Americans (2, 29). We were unable to locate any
previous articles exploring the association between serum
magnesium and incidence of HF. Patients with HF are, however,
more likely to have low serum magnesium than are other older
individuals (33), and among patients with HF, low serum mag-
nesium has been associated with all-cause mortality (34). In
addition, small randomized clinical trials of patients with HF
have suggested that magnesium supplementation improves left
ventricular function (35) and heart rate variability (36). The idea
that magnesium may have cardioprotective properties is not new.
Serum magnesium deficiency is thought to elevate the risk of
atrial fibrillation after cardiac surgery (37, 38), and in that set-
ting, magnesium is sometimes used prophylactically to prevent
atrial fibrillation events, although evidence for this intervention
is inconclusive (37, 38). Previous work by our group and others
has also identified low serum magnesium to be associated with
an increased risk of incident atrial fibrillation (39, 40). Atrial
fibrillation and heart failure are closely related; they often co-
occur as a cause of each other (41, 42).
Phosphorus and HF
Individuals in the highest quintile of serum phosphorus were at
w40% greater risk of developing incident HF than those in
those in the lowest quintile, regardless of degree of adjustment.
The association was nonlinear, with excess risk present only
among those in the upper quintile of serum phosphorus. Our
finding is concordant with previous epidemiologic investigations
that have shown high phosphorus concentrations to be associ-
ated with elevated risk of CVD (13, 20, 21, 24), atrial fibrillation
(also in ARIC) (39), and poorer outcomes among patients with
chronic kidney disease (43). Only the Framingham Study (13)
and a post hoc analysis of the Cholesterol and Recurrent Events
clinical trial (24) have found positive associations of serum
phosphorus to HF risk. There is presently heightened scientific
interest regarding the role of phosphorus homeostasis in HF risk,
given recent findings from basic science (44) and epidemiology
(45, 46) linking fibroblast growth factor 23, a marker of phos-
phorus homeostasis, to cardiac disease.
Calcium and HF
Serum calcium was positively and linearly associated with the
risk of incident HF. During the full follow-up, individuals in the
highest quintile were at w40% greater risk of incident HF than
their counterparts in the lowest serum calcium quintile. How-
ever, when restricted to the first 5 y of follow-up, individuals in
the highest quintile were at w2.5-fold greater risk, indicating
that perhaps serum calcium may be a marker of more proximal
risk. The role of calcium in cardiovascular risk is currently under
intense scientific scrutiny, given controversial [and at times
conflicting (47)] reanalysis (48) and meta-analyses (48, 49) of
clinical trial data, which have suggested that calcium supple-
mentation is associated with an increased risk of MI. It has been
speculated that large doses of calcium supplements transiently
increase serum calcium concentrations, even above the normal
range, for several hours after ingestion, thereby promoting
vascular calcification and increased coagulability (7, 8). A dif-
ferent but related question was examined here: whether serum
calcium concentrations within the general population are asso-
ciated with HF. Most (21–23), although not all (20), observa-
tional studies of serum calcium concentrations have shown
a positive association with the risk of MI and combined CVD
endpoints but have not specifically examined HF incidence.
Strengths and limitations
Strengths of this study are the use of data from a large pop-
ulation-based prospective cohort and resulting high number of
events that enabled subgroup analyses. Limitations of this study
warrant consideration. First, measurements of serummagnesium,
phosphorus, and calcium took place at the baseline visit. As such,
concentrations may not have been representative of those more
proximal to the development of most HF events. That said, results
were similar in sensitivity analyses, which averaged biomarker
concentrations from visit 1 and visit 2 (data not shown; these
biomarkers are not available at any other ARIC visit). Second,
these are observational data. Despite our attempts at adjustment,
it is possible that confounding (due to both residual confounding
and unmeasured confounders) remained. Last, ARIC HF events
were identified through ICD codes from hospital discharge and
death certificates, and thus some cases may have been missed.
However, ARIC has shown HF ICD codes to have high validity
(30).
It is also important to be cognizant of the fact that concen-
trations of serum magnesium, phosphorus, and calcium are
influenced by numerous metabolic factors as well as by dietary
intake. For example, w40–60% of magnesium consumed is ab-
sorbed, although absorption efficiency can rise to w80% when
intakes are low (50). In addition to dietary intake, serum mag-
nesium concentrations also reflect intracellular concentrations
and renal handling, which may have a stronger effect on serum
magnesium than dietary intake. Importantly, however, less than
25% of US adults meet the Recommended Daily Allowance for
dietary magnesium intake (50).
Conclusions
Within the large, prospective, population-based ARIC cohort,
we found that, as hypothesized, serum magnesium was inversely
and independently associated with the development of HF,
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whereas serum calcium and phosphorus were positively and
independently associated with the risk of HF. Additional work is
needed to elucidate whether these associations are causal and, if
so, to clarify the specific mechanisms that underlie the associ-
ations. Whether these biomarkers will be useful candidates for
HF risk prediction or targets for prevention remains to be seen.
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